Oral Session 1-10C MM: Proteasome inhibitors

[OS1-10C-1] Once-weekly vs twice-weekly carfilzomib (K): analysis of Asian patients in the Phase 3 ARROW study

Hirohiko Shibayama¹, Philippe Moreau², Meletios Dimopoulos³, Shotaro Hagiwara^4,5, Hiroshi Handa⁶, Shuji Ozaki⁷, Martina A. Sersch⁸, Mei Huang⁸, Shinsuke Iida⁹ (1.Hematol. & Oncol., Osaka Univ. Grad. Sch., Osaka, Japan, 2.Hematol., Univ. Hosp. Hotel-Dieu, Nantes, France, 3.Clin. Ther., Univ. Athens, Athens, Greece, 4.Hematol., Ctr. Hosp. Natl. Ctr. Global Health Med., Tokyo, Japan, 5.Hematol., Tokyo Women's Med. Univ., Tokyo, Japan, 6.Hematol., Gunma Univ. Grad. Sch., Maebashi, Japan, 7.Hematol., Tokushima Pref. Ctr. Hosp., Tokushima, Japan, 8.Amgen Inc., Thousand Oaks, USA, 9.Hematol. & Oncol., Nagoya City Univ. Grad. Sch., Nagoya, Japan)